A versatile platform for generating engineered extracellular vesicles with defined therapeutic properties

Authors: Dooley, Kevin, McConnell, Russell E., Xu, Ke, Lewis, Nuruddeen D., Haupt, Sonya, Youniss, Madeleine R., Martin, Shelly, Sia, Chang Ling, McCoy, Christine, Moniz, Raymond J., Burenkova, Olga, Sanchez-Salazar, Jorge, Jang, Su Chul, Choi, Bryan, Harrison, Rane A., Houde, Damian, Burzyn, Dalia, Leng, Charan, Kirwin, Katherine, Ross, Nikki L., Finn, Jonathan D., Gaidukov, Leonid, Economides, Kyriakos D., Estes, Scott, Thornton, James E., Kulman, John D., Sathyanarayanan, Sriram, Williams, Douglas E.

Source: In Molecular Therapy 5 May 2021 29(5):1729-1743

Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors

Authors: Bregar, Amy, Deshpande, Amit, Grange, Chris, Zi, Tong, Stall, Jennifer, Hirsch, Heather, Reeves, Jason, Sathyanarayanan, Sriram, Growdon, Whitfield B., Rueda, Bo R.

Source: In Gynecologic Oncology June 2017 145(3):446-452

Development of a High-Throughput Gene Expression Screen for Modulators of RAS-MAPK Signaling in a Mutant RAS Cellular Context

Authors: Severyn, Bryan ^*, Nguyen, Thi, Altman, Michael D., Li, Lixia, Nagashima, Kumiko, Naumov, George N., Sathyanarayanan, Sriram, Cook, Erica, Morris, Erick, Ferrer, Marc, Arthur, Bill, Benita, Yair, Watters, Jim, Loboda, Andrey, Hermes, Jeff, Gilliland, D. Gary, Cleary, Michelle A., Carroll, Pamela M., Strack, Peter, Tudor, Matt, Andersen, Jannik N. ^**

Source: In SLAS Discovery October 2016 21(9):989-997

Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors

Authors: Zhang, Weisheng, Haines, Brian B., Efferson, Clay, Zhu, Joe, Ware, Chris, Kunii, Kaiko, Tammam, Jennifer, Angagaw, Minilik, Hinton, Marlene C., Keilhack, Heike, Paweletz, Cloud P., Zhang, Theresa, Winter, Chris, Sathyanarayanan, Sriram, Cheng, Jonathan, Zawel, Leigh, Fawell, Stephen, Gilliland, Gary, Majumder, Pradip K.

Source: In Translational Oncology December 2012 5(6):422-429

Genetic and Pharmacological Inhibition of PDK1 in Cancer Cells: CHARACTERIZATION OF A SELECTIVE ALLOSTERIC KINASE INHIBITOR

Authors: Nagashima, Kumiko, Shumway, Stuart D., Sathyanarayanan, Sriram, Chen, Albert H., Dolinski, Brian, Xu, Youyuan, Keilhack, Heike, Nguyen, Thi, Wiznerowicz, Maciej, Li, Lixia, Lutterbach, Bart A., Chi, An, Paweletz, Cloud, Allison, Timothy, Yan, Youwei, Munshi, Sanjeev K., Klippel, Anke, Kraus, Manfred, Bobkova, Ekaterina V., Deshmukh, Sujal, Xu, Zangwei, Mueller, Uwe, Szewczak, Alexander A., Pan, Bo-Sheng, Richon, Victoria, Pollock, Roy, Blume-Jensen, Peter, Northrup, Alan, Andersen, Jannik N.

Source: In Journal of Biological Chemistry 25 February 2011 286(8):6433-6448

Methods for the identification and treatment of patients sensitive to anti IGF-1R inhibition therapy

ANTIBODIES

COMPOSITIONS AND METHODS FOR TREATING CANCER

Identification of novel genes involved in light-dependent CRY degradation through a genome-wide RNAi screen.

Authors: Sathyanarayanan, Sriram, Zheng, Xiangzhong, Kumar, Shailesh

Source: Genes & Development; June 1 2008, Vol. 22 Issue 11, p1522-1533, 12p

Post-translational regulation of the Drosophila circadian clock requires protein phosphatase 1 (PP1)

Authors: Fang, Yanshan, Sathyanarayanan, Sriram, Sehgal, Amita

Source: Genes & Development; June 15 2007, Vol. 21 Issue 12, p1506-1518, 13p

Posttranslational Regulation of Drosophila PERIOD Protein by Protein Phosphatase 2A.

Authors: Sathyanarayanan, Sriram, Zheng, Xiangzhong, Xiao, Rui

Source: Cell; February 20 2004, Vol. 116 Issue 4, p603-615, 13p

ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models.

Authors: Hanson, Amanda, Elpek, Kutlu, Duong, Ellen, Shallberg, Lindsey, Fan, Martin, Johnson, Calvin, Wallace, Matthew, Mabry, George R., Sazinsky, Stephen, Pepper, Lauren, Shu, Chengyi J., Sathyanarayanan, Sriram, Zuerndorfer, Sarah, Simpson, Tyler, Gostissa, Monica, Briskin, Michael, Law, Deborah, Michaelson, Jennifer, Harvey, Christopher J.

Source: PLoS ONE; 9/24/2020, Vol. 15 Issue 9, p1-21, 21p

Subject Terms: T cells, ANIMAL models in research, T cell receptors, FC receptors, IMMUNITY, ANTIBODY-dependent cell cytotoxicity, CYTOTOXIC T cells

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormonesensitive breast cancer.

Authors: Becker, Marc A., Xiaonan Hou, Tienchaianada, Piyawan, Haines, Brian B., Harrington, Sean C., Weroha, S. John, Sathyanarayanan, Sriram, Haluska, Paul

Source: BMC Cancer; 10/20/2016, Vol. 16, p1-11, 11p, 1 Diagram, 5 Graphs

Subject Terms: BREAST cancer treatment, DRUG synergism, THERAPEUTIC use of monoclonal antibodies, SOMATOMEDIN, MTOR protein

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Inhibition of Notch signaling in combination with paclitaxel reduces platinum-resistant ovarian tumor growth.

Authors: Groeneweg, JolijnW., DiGloria, Celeste M., Jing Yuan, Richardson, William S., Growdon, Whitfield B., Sathyanarayanan, Sriram, Foster, Rosemary, Rueda, Bo R.

Source: Frontiers in Oncology; Jul2014, Vol. 4, p1-10, 10p

Subject Terms: OVARIAN cancer, XENOGRAFTS, CANCER treatment, PACLITAXEL, CARBOPLATIN